We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+28.06%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.82B
AUM Growth
+$156M
Cap. Flow
+$13.3M
Cap. Flow %
0.73%
Top 10 Hldgs %
79.73%
Holding
45
New
4
Increased
25
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33M
2
EHTH icon
eHealth
EHTH
+$22.7M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$14.1M
4
EPZM
Epizyme, Inc
EPZM
+$11.9M
5
GOSS icon
Gossamer Bio
GOSS
+$11.6M

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$70.2M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$49.2M
3
IMMU
Immunomedics Inc
IMMU
+$16.7M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.79M
5
STAA icon
STAAR Surgical
STAA
+$1.59M

Sector Composition

Rank Sector Weight
1 Healthcare 74.2%
2 Financials 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$413M 22.65%
4,852,383
-330,600
-6% -$16.7M
INSM icon
2
Insmed
INSM
$29B
$194M 10.64%
6,032,956
+30,667
+0.5% +$881K
STAA icon
3
STAAR Surgical
STAA
$1.24B
$158M 8.67%
2,791,693
-29,461
-1% -$1.59M
ABMD
4
DELISTED
Abiomed Inc
ABMD
$140M 7.67%
504,033
+11,700
+2% +$3.37M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$13.5B
$132M 7.23%
1,732,550
+326,600
+23% +$33M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$111M 6.1%
7,867,114
+532,400
+7% +$7.76M
UTHR icon
7
United Therapeutics
UTHR
$22.1B
$79.3M 4.35%
785,406
+19,000
+2% +$2.08M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$76.4M 4.19%
6,403,600
+889,924
+16% +$11.9M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$5.07B
$75.6M 4.15%
1,832,300
+267,400
+17% +$11.5M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$47.6M
$74.3M 4.08%
339,077
+57,780
+21% +$14.1M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$52.4M 2.87%
457,529
+12,900
+3% +$1.39M
RVNC
12
DELISTED
Revance Therapeutics, Inc.
RVNC
$50.2M 2.75%
1,994,905
+290,533
+17% +$7.62M
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$298M
$40.3M 2.21%
4,170,281
+53,733
+1% +$574K
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$36.1M 1.98%
590,200
+15,000
+3% +$760K
AMAG
15
DELISTED
AMAG Pharmaceuticals
AMAG
$28.2M 1.55%
3,003,875
+44,288
+1% +$421K
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$26.1M 1.43%
4,469,411
+108,000
+2% +$646K
EHTH icon
17
eHealth
EHTH
$39.1M
$22.2M 1.22%
+280,438
New +$22.7M
ALGN icon
18
Align Technology
ALGN
$12.3B
$22.1M 1.21%
67,505
– –
PBYI icon
19
Puma Biotechnology
PBYI
$453M
$13.8M 0.76%
1,368,317
+24,420
+2% +$249K
GOSS icon
20
Gossamer Bio
GOSS
$88.9M
$13.4M 0.73%
1,077,200
+872,986
+427% +$11.6M
PRTA icon
21
Prothena Corp
PRTA
$473M
$13.3M 0.73%
1,328,734
+557,669
+72% +$6.71M
KLDO
22
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$8.71M 0.48%
786,400
– –
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.97M 0.33%
331,813
– –
ANAB icon
24
AnaptysBio
ANAB
$1.71B
$5.44M 0.3%
+368,722
New +$6.65M
ATNX
25
DELISTED
Athenex, Inc. Common Stock
ATNX
$3.11M 0.17%
12,840
+3,580
+39% +$860K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q3 2020 Portfolio in Review

As of Q3 2020, Palo Alto Investors held 45 positions worth $1.82B, up 9.4% from $1.67B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Palo Alto Investors's Q3 2020 filing shows 4 new, 25 increased, 5 reduced and 2 closed positions. Its largest new stake was eHealth: 280,438 shares worth $22.2M. The largest sale was Aimmune Therapeutics, an estimated $70.2M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 84% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q3 2020 buy was eHealth: 280,438 shares worth $22.2M.
  • Palo Alto Investors added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $33M increase.
  • Palo Alto Investors's biggest Q3 2020 reduction was Aimmune Therapeutics, cutting an estimated $70.2M.
  • Palo Alto Investors fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $49.2M.
  • Palo Alto Investors's ten largest holdings make up 80% of its $1.82B portfolio in Q3 2020.
  • Palo Alto Investors opened 4 new positions and closed 2 in Q3 2020.
  • Palo Alto Investors's portfolio value rose 9.4% quarter-over-quarter to $1.82B.

Based on Palo Alto Investors's 13F filing for Q3 2020, filed 16 Nov 2020.